Numerate and Takeda enter agreement to generate novel clinical candidates using AI-driven drug discovery. Numerate, Inc., a computational drug design company applying artificial intelligence (AI) at cloud scale to transform small molecule drug discovery, announced the formation of a multi-year agreement with Takeda Pharmaceutical Company Limited under which Numerate will identify and deliver multiple clinical…
Eurofins Acquires German GATC, Strengthening Genomics & Genetic Testing Footprint
Eurofins strengthens its genomics and genetic testing footprint with the acquisition of GATC in Germany. Eurofins Scientific has signed an agreement to acquire GATC Biotech AG, one of Europe’s specialists in DNA sequencing. The transaction is expected to close in July, subject to the fulfilment of customary closing conditions. Founded in 1990, GATC has achieved a…
Phase 2 Study: First Ever Evidence of Treatment-Induced Reduction in HIV Reservoirs
Biosimilars Market Report: 2016-2025 Trends, Size, & Forecast
Biosimilars market report, by product types, application and, geography – analysis, share, trends, size, & forecast 2016 – 2025 – Research and Markets. Research and Markets has announced the addition of the “Biosimilars Market Report, by Product Types, Application and, Geography – Analysis, Share, Trends, Size, & Forecast 2016 – 2025” report to their offering. The market…
Nordic Nanovector & Heidelberg Pharma Collaborate to Develop Leukemia Treatment
Merck’s Phase 3 Trial Studying Urothelial Cancer Treatment Meets Primary Endpoint & Stops Early
Merck’s KEYNOTE-045 studying KEYTRUDA® (pembrolizumab) in advanced bladder cancer (urothelial cancer) meets primary endpoint and stops early. Merck, known as MSD outside the United States and Canada, announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA ® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary…
Study Supports Switching to Biosimilar Infliximab From Originator
VIENNA — (BUSINESS WIRE) — New data presented at the 2016 United European Gastroenterology (UEG) Week show that a switch to biosimilar infliximab (CT-P13) from originator infliximab is not inferior to continued treatment with the originator and that patients can be safely switched. The clinical study, sponsored by the Norwegian government, involved nearly 500 patients…
Merck Launches Online Educational Resource About Biosimilar Medicines for Patients
Merck launches Biosimilars Clarified, a new online educational resource about biosimilar medicines for patients and the healthcare community. Merck, known as MSD outside the United States and Canada, today announced the launch of Biosimilars Clarified, a new educational website for patients, caregivers and the healthcare community that is designed to provide clear, concise and straightforward information…
Engility Wins $10 Million Task Order to Combat Chikungunya Virus
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership
Samsung Bioepis’ Biosimilar MAA Accepted by EMA
Samsung Bioepis’ Marketing Authorization Application for SB3 trastuzumab biosimilar candidate accepted for review by the European Medicines Agency. Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency (EMA) has accepted for review the company’s Marketing Authorization Application (MAA) for SB3, a biosimilar candidate referencing Herceptin® (trastuzumab). Herceptin® is a monoclonal antibody (mAb) indicated for the…
Cancer Research UK, MSD and Verastem Collaborate to Trial New Combination of Immunotherapy Drugs
CANCER RESEARCH UK has announced its first cross-company deal as part of its Experimental Cancer Medicine Centre (ECMC) Combinations Alliance. MSD, Verastem, Inc. and Cancer Research UK will trial a new combination of immunotherapy drugs in mesothelioma, non-small cell lung and pancreatic cancers. The trial will run through the ECMC network at centers in Edinburgh-Dundee,…
Boehringer Ingelheim & Sarah Cannon Research Institute to Develop Immune-Oncology Therapies
Boehringer Ingelheim and Sarah Cannon Research Institute launch strategic collaboration to develop novel immune-oncology therapies. Boehringer Ingelheim and Sarah Cannon Research Institute, the research arm of Sarah Cannon, the global cancer institute of HCA, announced today a new strategic collaboration. This partnership brings together Boehringer Ingelheim’s extensive experience in cancer drug development and Sarah Cannon’s expertise and…
Pfizer Completes Acquisition of Medivation
Pfizer Inc. announced the successful completion of its acquisition of Medivation, Inc. As of the tender offer expiration, 115,574,041 shares of Medivation common stock were validly tendered, representing approximately 69.1% of the shares outstanding and have been accepted for payment under the terms of the tender offer for $81.50 per share in cash, without interest,…
Bristol-Myers Squibb & Nektar Collaborate on Oncology Drug Combination
Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis
Mirna Therapeutics Halts Phase 1 Clinical Study of Cancer Drug
GE to Invest 150M Euros in Bio-Manufacturing Campus in Ireland
GE to invest €150 million in biopharmaceutical manufacturing campus in Cork, Ireland, and establish advanced manufacturing training center at NIBRT. Ireland’s Minister for Jobs, Enterprise and Innovation, Mary Mitchell O’Connor TD, announced that GE is to invest €150 million in a new biopharmaceutical manufacturing campus on Industrial Development Agency (IDA) Ireland’s strategic site at Loughbeg, Ringaskiddy, Co.…
OncoImmune Announces Option and License Agreement with Pfizer Inc.
OncoImmune, Inc. announced that it has entered into an exclusive option and license agreement with Pfizer Inc. for ONC-392, a novel, differentiated preclinical anti-CTLA4 monoclonal antibody in a deal worth up to $250 million in upfront and potential milestone payments. Under the terms of the agreement, Pfizer plans to evaluate ONC-392 up until a certain agreed-upon…
Merck & Pfizer’s Type 2 Diabetes Drug Met Primary Endpoint in Phase 3 Study
Merck and Pfizer announce investigational ertugliflozin met primary endpoint of A1C reduction when added to sitagliptin and metformin in people with type 2 diabetes. Merck, known as MSD outside the United States and Canada, in partnership with Pfizer Inc. announced that a Phase 3 study (VERTIS SITA2) of ertugliflozin, an investigational oral SGLT2 inhibitor for the…
Aphios to Develop HIV/AIDS Cure Using Combination Drugs
Pfizer Appoints Chief Scientific Officer for Neuroscience Research
Pfizer Inc. announced that Dr. Ole Isacson, a world-renowned scientist and thought leader in neurology, will become Chief Scientific Officer of the Neuroscience Research Unit and Senior Vice President, effective September 16. Dr. Isacson is a Professor of Neurology at Harvard Medical School, and will continue to serve in an educational role. He is also…
Fitch: Pfizer Deal Highlights U.S. Pharma Trend for Targeted M&A
Pfizer’s proposed acquisition of Medivation highlights the trend of large innovative U.S. pharmaceutical firms continuing to pursue targeted acquisitions rather than large transformative ones, according to Fitch Ratings. Consolidation continues as big pharmaceutical firms search for scale and efficiencies. However, as the number of new drugs in the pipeline increases, and manufacturers face manageable patent expiry risks,…
Pfizer to Acquire Small Molecule Anti-Infective Business from AstraZeneca
Indian FDA Approves Product Licenses for Arousal Drugs
Innovus Pharmaceuticals, Inc. announced that its partner Khandelwal Laboratories received the approval of the product licenses for Zestra®, Zestra Glide®, EjectDelay®, and Sensum+® from the Indian FDA, The Drugs Controller General (India), and the Directorate General of Health Services to commercialize the products in India. “We are thrilled to have received the approval to commercialize our products from…